` JUBLPHARMA (Jubilant Pharmova Ltd) vs BSE Sensex 30 Comparison - Alpha Spread

JUBLPHARMA
vs
BSE Sensex 30

Over the past 12 months, JUBLPHARMA has significantly outperformed BSE Sensex 30, delivering a return of 34% compared to the BSE Sensex 30's 6% growth.

Stocks Performance
JUBLPHARMA vs BSE Sensex 30

Loading

Performance Gap
JUBLPHARMA vs BSE Sensex 30

Sign Up to see
Performance Gap
Sign In
Sign Up

Performance By Year
JUBLPHARMA vs BSE Sensex 30

Loading
JUBLPHARMA
BSE Sensex 30
Add Stock

Competitors Performance
Jubilant Pharmova Ltd vs Peers

BSE Sensex 30
JUBLPHARMA
LLY
JNJ
NOVO B
ROG
Add Stock

Jubilant Pharmova Ltd
Glance View

Market Cap
144.1B INR
Industry
Pharmaceuticals

Once rooted as a modest family business, Jubilant Pharmova Ltd. has evolved into a global powerhouse in the pharmaceutical and life sciences industry. Founded by the visionary Bhartia family, the company has sprawled across continents, transforming healthcare landscapes with its robust product portfolio. Jubilant Pharmova's journey is one painted with strategic diversification, cleverly balancing risk and driving sustainable growth. At its core, the company operates through three primary segments: Pharmaceuticals, Contract Research and Development Services, and Proprietary Drug Discovery. Each arm serves as a critical piece in the company's strategic mosaic, enhancing its resilience amid the ever-fluctuating pharmaceutical market dynamics. Underpinning Jubilant Pharmova's business model is its Pharmaceuticals segment, which churns a significant portion of its revenue. The company manufactures and sells an array of pharmaceutical products, including generics and specialty pharmaceuticals, which cater to multiple therapeutic areas. Further driving its financial engine is the Contract Research and Development Service segment, which offers outsourced R&D solutions to a host of pharmaceutical majors—a sector that has witnessed burgeoning demand alongside escalating R&D costs globally. On the innovation frontier, the Proprietary Drug Discovery segment embarks on uncharted territories, seeking novel drugs and solutions, paving the path for the future. Such a diversified approach not only positions Jubilant Pharmova as a formidable entity in the pharmaceutical domain but also provides a cushion against industry-specific headwinds, reinforcing its long-term sustainability.

JUBLPHARMA Intrinsic Value
HIDDEN
Show
Back to Top